Breaking News

DPT Completes Corrective Actions

March 20, 2013

FDA closes out investigation of Lakewood site

DPT Laboratories has received notification from the FDA on February 19, 2013, signaling the completion of DPT’s corrective actions taken at its Lakewood, NJ facility in response to the warning letter received on August 27, 2012. The letter also communicated that the Lakewood site is compliant with FDA regulations.
 
“We are pleased to have this issue behind us and appreciate the confidence our new and existing customers demonstrated in us during this time,” said Eugene Ciolfi, DPT vice president and general manager.  “I am excited and optimistic about the opportunities ahead of us in 2013.”
 
“This resolution has strengthened DPT,” said Paul Johnson, DPT Group president and chief operating officer. “Our commitment to quality and continuous improvement will remain a priority as we continue building a world-class business.”

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks